These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25433098)

  • 1. Aldosterone: a cardiometabolic risk hormone?
    Feliciano Pereira P; Eloiza Priore S; Bressan J
    Nutr Hosp; 2014 Dec; 30(6):1191-202. PubMed ID: 25433098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
    Whaley-Connell A; Johnson MS; Sowers JR
    Prog Cardiovasc Dis; 2010; 52(5):401-9. PubMed ID: 20226958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The adipose tissue and the involvement of the renin-angiotensin-aldosterone system in cardiometabolic syndrome.
    Borghi F; Sevá-Pessôa B; Grassi-Kassisse DM
    Cell Tissue Res; 2016 Dec; 366(3):543-548. PubMed ID: 27734151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?
    Krug AW; Ehrhart-Bornstein M
    Hypertension; 2008 May; 51(5):1252-8. PubMed ID: 18347227
    [No Abstract]   [Full Text] [Related]  

  • 5. The association of aldosterone with obesity-related hypertension and the metabolic syndrome.
    Vogt B; Bochud M; Burnier M
    Semin Nephrol; 2007 Sep; 27(5):529-37. PubMed ID: 17868790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk between adipose tissue and blood vessels in cardiometabolic syndrome: implication of steroid hormone receptors (MR/GR).
    Even SE; Dulak-Lis MG; Touyz RM; Nguyen Dinh Cat A
    Horm Mol Biol Clin Investig; 2014 Aug; 19(2):89-101. PubMed ID: 25390018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of aldosterone and angiotensin II in insulin resistance: an update.
    Lastra-Lastra G; Sowers JR; Restrepo-Erazo K; Manrique-Acevedo C; Lastra-González G
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):1-6. PubMed ID: 19138313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease.
    Gorini S; Marzolla V; Mammi C; Armani A; Caprio M
    Biomolecules; 2018 Sep; 8(3):. PubMed ID: 30231508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders.
    Garg R; Adler GK
    Curr Hypertens Rep; 2015 Jul; 17(7):52. PubMed ID: 26068659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Aldosterone in Obesity-Related Hypertension.
    Kawarazaki W; Fujita T
    Am J Hypertens; 2016 Apr; 29(4):415-23. PubMed ID: 26927805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving research in nongenomic actions of aldosterone.
    Williams JS
    Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):198-203. PubMed ID: 23519092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptors in the metabolic syndrome.
    Zennaro MC; Caprio M; Fève B
    Trends Endocrinol Metab; 2009 Nov; 20(9):444-51. PubMed ID: 19800255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering.
    Egan BM; Stepniakowski K; Goodfriend TL
    Am J Hypertens; 1994 Oct; 7(10 Pt 1):886-93. PubMed ID: 7826551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant Rac1-mineralocorticoid receptor pathways in salt-sensitive hypertension.
    Kawarazaki W; Fujita T
    Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):929-36. PubMed ID: 24111570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenocortical dysfunction in obesity and the metabolic syndrome.
    Krug AW; Ehrhart-Bornstein M
    Horm Metab Res; 2008 Aug; 40(8):515-7. PubMed ID: 18446685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [System renin-aldosterone in fat tissue and other organ and tissues].
    Svacina S
    Vnitr Lek; 2008 May; 54(5):508-10. PubMed ID: 18630637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary aldosteronism and metabolic syndrome.
    Fallo F; Pilon C; Urbanet R
    Horm Metab Res; 2012 Mar; 44(3):208-14. PubMed ID: 22116746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between the Bertin index to estimate visceral adipose tissue from dual-energy X-ray absorptiometry and cardiometabolic risk factors before and after weight loss.
    Karelis AD; Rabasa-Lhoret R; Pompilus R; Messier V; Strychar I; Brochu M; Aubertin-Leheudre M
    Obesity (Silver Spring); 2012 Apr; 20(4):886-90. PubMed ID: 21869764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortisol dysregulation in obesity-related metabolic disorders.
    Baudrand R; Vaidya A
    Curr Opin Endocrinol Diabetes Obes; 2015 Jun; 22(3):143-9. PubMed ID: 25871955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mineralocorticoid receptor: a new player controlling energy homeostasis.
    Kuhn E; Lombès M
    Horm Mol Biol Clin Investig; 2013 Sep; 15(2):59-69. PubMed ID: 25436733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.